Results 231 to 240 of about 471,997 (328)

ACUTE COLITIS AND ULCERATIVE COLITIS [PDF]

BMJ, 1907
openaire   +2 more sources

Perioperative utilization of JAK inhibitors in Perianal Fistulizing Crohn's disease

JPGN Reports, EarlyView.
Abstract With the recent approval of small molecule drugs such as upadacitinib in adult inflammatory bowel disease (IBD), their utilization is becoming more common; however, there is limited data on perioperative risks or optimal timing of cessation and resumption to mitigate flares. Current recommendations suggest holding these medications for 14 days
Alexander Lyons, Lindsey Lawrence, Samantha Saul   +2 more
wiley   +1 more source

A retrospective case series of amebic colitis clinical features at a tertiary hospital in Beijing from 2021 to 2024. [PDF]

BMC Infect Dis
Gao YH, Yu M, Wang LN, Dong LF, Li J.
europepmc   +1 more source

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Serena Yun‐Chen Tsai, Ashwin N. Ananthakrishnan, Harland S. Winter, Kevin Sheng‐Kai Ma   +3 more
wiley   +1 more source

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4‐year‐old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose ...
Alison Laxer, Morris Edelman, Julie Gallagher, Benjamin Sahn   +3 more
wiley   +1 more source

Crystal engineering optimizes emodin-tetramethylpyrazine combination: From cocrystal design to <i>in vivo</i> anti-colitis efficacy assessment. [PDF]

Int J Pharm X
Liu M, Jiang Y, Yuan P, Li S, Zhang B, Zhou X, Su B, Xie Y, Yang D, Kong L, Zhang L, Lv Y, Du G.   +12 more
europepmc   +1 more source

Frequency and impact of repeat colonoscopy as a treat‐to‐target approach in pediatric inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Objectives Endoscopic healing (EH) is a treatment target in inflammatory bowel disease (IBD). However, adherence to repeat colonoscopy (RC) for EH assessment in pediatrics remains variable. We aimed to evaluate the frequency and timing of RC after diagnosis and its impact on treatment decisions at a large pediatric IBD center.
Kari Noel VanEvery, Grace Dukes, Brendan Boyle, Jennifer L. Dotson, Ross M. Maltz, Hilary K. Michel   +5 more
wiley   +1 more source

Effect of Chang'an decoction on ulcerative colitis by regulating T helper 17 cells and regulatory T cellsRab27 in the p53/high mobility group box 1 pathway. [PDF]

J Tradit Chin Med
Li Z, Ting J, Xiaojing W, Yingqi W, Fengbin L, Hong MI.   +5 more
europepmc   +1 more source

Impact of timing on mucosal healing during restaging endoscopy in pediatric Crohn's disease: A retrospective cohort study

JPGN Reports, EarlyView.
Abstract While endoscopic remission is an important target in pediatric Crohn's disease (CD), no consensus for restaging timing exists. This retrospective cohort study assessed the timing and impact of restaging endoscopy in children with new CD in remission, comparing earlier ( ≤ 9 months) versus later endoscopy.
Anna Janecek, Alexandra S. Hudson, David L. Suskind, Hengqi B. Zheng, Samuel Simpson, Dale Lee, Ghassan Wahbeh, Hannibal Person   +7 more
wiley   +1 more source

Endoscopic resection of colitis-associated neoplasia: A scoping review. [PDF]

World J Gastrointest Endosc
Pal P, Kata P, Nabi Z, Ramchandani M, Gupta R, Tandan M, Duvvur NR.   +6 more
europepmc   +1 more source